These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 23832667)

  • 21. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
    Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
    Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
    Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC
    Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
    Salvi A; Sabelli C; Moncini S; Venturin M; Arici B; Riva P; Portolani N; Giulini SM; De Petro G; Barlati S
    FEBS J; 2009 Jun; 276(11):2966-82. PubMed ID: 19490101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
    Ke AW; Shi GM; Zhou J; Wu FZ; Ding ZB; Hu MY; Xu Y; Song ZJ; Wang ZJ; Wu JC; Bai DS; Li JC; Liu KD; Fan J
    Hepatology; 2009 Feb; 49(2):491-503. PubMed ID: 19065669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulation of the putative oncogene COTE1 contributes to human hepatocarcinogenesis through modulation of WWOX signaling.
    Zhang H; Tian Y; Shen J; Wang Y; Xu Y; Wang Y; Han Z; Li X
    Int J Oncol; 2014 Aug; 45(2):719-31. PubMed ID: 24899407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA interference-mediated silencing of Stat5 induces apoptosis and growth suppression of hepatocellular carcinoma cells.
    Zhang L; Zhao Z; Feng Z; Yin N; Lu G; Shan B
    Neoplasma; 2012; 59(3):302-9. PubMed ID: 22296499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
    Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
    Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2.
    Hu CT; Cheng CC; Pan SM; Wu JR; Wu WS
    Cell Signal; 2013 Jun; 25(6):1457-67. PubMed ID: 23524339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells.
    Tai CJ; Chin-Sheng H; Kuo LJ; Wei PL; Lu HH; Chen HA; Liu TZ; Liu JJ; Liu DZ; Ho YS; Wu CH; Chang YJ
    Ann Surg Oncol; 2012 Jan; 19(1):336-43. PubMed ID: 21516372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met.
    Korhan P; Erdal E; Atabey N
    Biochem Biophys Res Commun; 2014 Aug; 450(4):1304-12. PubMed ID: 25058462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Up-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathway.
    Chou CH; Huang MJ; Chen CH; Shyu MK; Huang J; Hung JS; Huang CS; Huang MC
    Oncotarget; 2015 Mar; 6(8):6123-35. PubMed ID: 25762620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
    Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
    Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
    Fornari F; Milazzo M; Chieco P; Negrini M; Calin GA; Grazi GL; Pollutri D; Croce CM; Bolondi L; Gramantieri L
    Cancer Res; 2010 Jun; 70(12):5184-93. PubMed ID: 20501828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
    Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
    Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.
    Yu J; Xia X; Dong Y; Gong Z; Li G; Chen GG; Lai PBS
    Theranostics; 2021; 11(5):2123-2136. PubMed ID: 33500715
    [No Abstract]   [Full Text] [Related]  

  • 37. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients.
    Wang RY; Chen L; Chen HY; Hu L; Li L; Sun HY; Jiang F; Zhao J; Liu GM; Tang J; Chen CY; Yang YC; Chang YX; Liu H; Zhang J; Yang Y; Huang G; Shen F; Wu MC; Zhou WP; Wang HY
    Gastroenterology; 2013 Dec; 145(6):1436-48.e1-12. PubMed ID: 23933603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
    Hiscox S; Jordan NJ; Jiang W; Harper M; McClelland R; Smith C; Nicholson RI
    Endocr Relat Cancer; 2006 Dec; 13(4):1085-99. PubMed ID: 17158755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor.
    Neaud V; Faouzi S; Guirouilh J; Le Bail B; Balabaud C; Bioulac-Sage P; Rosenbaum J
    Hepatology; 1997 Dec; 26(6):1458-66. PubMed ID: 9397985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo.
    Zhang SZ; Pan FY; Xu JF; Yuan J; Guo SY; Dai G; Xue B; Shen WG; Wen CJ; Zhao DH; Li CJ
    Mol Cancer Ther; 2005 Oct; 4(10):1577-84. PubMed ID: 16227408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.